Parameter
| Biomarker | TERT | Full name | Telomerase reverse transcriptase promoter mutation | Molecular Type | Nucleic acid (gene mutation) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis (early mutation detection) |
| Disease | Bladder Cancer (BC) | Disease Subtypes | / | ||
| Organ | Bladder | Test Sample / Technology Platform | Tissue (Sanger sequencing, digital PCR) | ||
| Pathobiological Mechanisms | One of the most frequent mutations in BC (~70 %); stably present in tissue; reflects tumor proliferative potential | ||||
| Clinical Availability Status | Research verification stage: tissue detection directly reflects tumor | ||||
| Notes and Dynamics | The synergistic effects of TERT promoter mutations with pathways such as FGFR and PI3K are under intensive investigation, holding promise as novel targets for combined targeted therapy; its detection technologies (e.g., digital PCR) are also being continuously optimized to enhance clinical utility. | ||||